Savara Inc. announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) International Conference, scheduled for May 16-21, 2025, in San Francisco, California. The company will also host an Industry Theater at the meeting.
The presentations will feature new data from the pivotal Phase 3 IMPALA-2 clinical trial of molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP). The data will specifically highlight molgramostim's impact on reducing surfactant burden and improving health-related quality of life.
These presentations aim to further disseminate the positive clinical evidence supporting MOLBREEVI's potential as a treatment for aPAP to a broad audience of respiratory specialists and researchers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.